London Stock Exchange Welcomes Verici Dx plc to AIM


London Stock Exchange welcomes Verici Dx plc (‘Verici Dx’ or the ‘Company’), a developer of advanced clinical diagnostics for organ transplant, to celebrate the listing of the Company's public shares onto AIM, under the ticker "VRCI".

Verici Dx is an immuno-diagnostics development company, initially focused on the kidney transplantation market. The Company's kidney transplant assays will use advanced next-generation sequencing that may define a personalised risk profile of each patient over the course of their transplant journey and may also detect injury in advance of currently available clinical tests.

The Company develops tests to understand how a patient is likely to, and may be, responding to kidney transplant. There are two leading products for clinical validation and commercialisation:

•    Clarava™, which is a pre-transplant prognosis for the risk of early acute rejection; and
•    Tuteva™, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatinine levels.

Verici Dx raised £14.5m gross significantly oversubscribed fundraising with net proceeds being used to undertake clinical utility and validation studies, to bioinformatics and health economic studies as well as staff and related benefits, for general corporate overheads and for license and royalties and capital expenditure (including to build additional testing capacity).

Sara Barrington, CEO of Verici Dx, said: “We are very grateful for the strong support shown by institutional and other investors to the Verici Dx IPO.  Obtaining funding in a public market is a strong signal of quality to prospective partners and customers, raises the profile of the business and its innovative products considerably, and gives us a supportive platform as we advance our strategy.  We look forward to providing further updates on the execution of our validation and commercialisation plans as we deploy the capital raised towards addressing a significant unmet clinical need.”

To find out more about Verici Dx visit:  www.vericidx.com

Quick facts

Track
Market: AIM
Instrument market cap (£m)
88.59
Listing/Admission to trading
03 Nov 2020
Looking for new and recent issues?

More recent

80.6
London Stock Exchange welcomes Fidelity International celebrating their latest range of ETFs

Fidelity International (Fidelity) expands its Sustainable Research Enhanced ETF range with the launch of 3 new funds offering exposure to Emerging Markets, Japan and Pacific Ex Japan.

Fund Ticker OCF Comparative market index Fidelity Sustainable Research Enhanced Emerging Market Equity ETF FEMR 0.50%  MSCI Emerging Markets

Learn more
78.04
London Stock Exchange welcomes One Heritage Group plc to the main market

London Stock Exchange welcomes One Heritage Group PLC (“One Heritage”) to trading on the Main Market by the way of a standard listing. The Group undertakes developments to create self-contained apartments while also refurbishing existing residential properties to create Co-living accommodation. It listed on 23 December 2020 having successfully raised £930,000 through a subscription and placemen

Learn more
88.08
London Stock Exchange welcomes Schroder BSC Social Impact Trust plc to the Premium Segment of the Main Market

Today London Stock Exchange markets were opened by Schroders and Big Society Capital to celebrate the listing of the Schroder BSC Social Impact Trust plc.

It is a new investment trust focused on investing in social impact investments that seek to address a range of issues including tackling the significant increase in homelessness, providing support for people with learning disab

Learn more
London Stock Exchange welcomes Ecofin U.S. Renewables Infrastructure Trust plc to the Main Market

Ecofin U.S. Renewables Infrastructure Trust plc (the "Company”) is pleased to announce that it has raised gross proceeds of $125 million pursuant to its initial public offering.

The Company intends to execute its investment objective by investing in a diversified portfolio of Renewable Assets predominantly in the United States, but it may also invest up to 15% of Gross Assets in

Learn more